Innovations and recent trends in the treatment of ADHD

Authors: Madaan, Vishal; Kinnan, Shannon; Daughton, Joan; Kratochvil, Christopher J

Source: Expert Review of Neurotherapeutics, Volume 6, Number 9, September 2006 , pp. 1375-1385(11)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Initiatives to develop better-tolerated, more efficacious pharmacological agents with improved drug delivery systems have driven recent research in attention-deficit hyperactivity disorder (ADHD). While stimulants are the primary pharmacotherapy for ADHD, these drugs have a limited duration of action and a subset of patients will either fail to respond to these medications or have side effects that preclude their use. The development of atomoxetine, the first nonstimulant approved for ADHD, has been followed by additional innovative research, such as the methylphenidate transdermal system, modafinil, NRP-104 and cholinergic agents. This review highlights some of the recent trends in ADHD treatment and the current status of promising treatment options that may help to shape the future of ADHD treatment.

Keywords: atomoxetine; attention-deficit hyperactivity disorder; modafinil; NRP-104; pharmacotherapy; stimulants; transdermal

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737175.6.9.1375

Publication date: 2006-09-01

More about this publication?

Expert Review of Neurotherapeutics provides expert commentary on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer's and Parkinson's.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites